000143613 001__ 143613
000143613 005__ 20240229112600.0
000143613 0247_ $$2doi$$a10.1038/s41408-019-0206-8
000143613 0247_ $$2pmid$$apmid:30962424
000143613 0247_ $$2pmc$$apmc:PMC6453945
000143613 0247_ $$2altmetric$$aaltmetric:58747113
000143613 037__ $$aDKFZ-2019-01190
000143613 041__ $$aeng
000143613 082__ $$a610
000143613 1001_ $$aWeisel, Katja C$$b0
000143613 245__ $$aAddition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.
000143613 260__ $$aLondon [u.a.]$$bNature Publishing Group$$c2019
000143613 3367_ $$2DRIVER$$aarticle
000143613 3367_ $$2DataCite$$aOutput Types/Journal article
000143613 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1558421238_12308$$xLetter
000143613 3367_ $$2BibTeX$$aARTICLE
000143613 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143613 3367_ $$00$$2EndNote$$aJournal Article
000143613 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143613 588__ $$aDataset connected to CrossRef, PubMed,
000143613 7001_ $$aScheid, Christof$$b1
000143613 7001_ $$aZago, Manola$$b2
000143613 7001_ $$aBesemer, Britta$$b3
000143613 7001_ $$00000-0002-6226-1252$$aMai, Elias K$$b4
000143613 7001_ $$aHaenel, Mathias$$b5
000143613 7001_ $$aDuerig, Jan$$b6
000143613 7001_ $$aMunder, Markus$$b7
000143613 7001_ $$aLindemann, Hans-Walter$$b8
000143613 7001_ $$aSeckinger, Anja$$b9
000143613 7001_ $$0P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aKunz, Christina$$b10$$udkfz
000143613 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b11$$udkfz
000143613 7001_ $$aHose, Dirk$$b12
000143613 7001_ $$aJauch, Anna$$b13
000143613 7001_ $$aSalwender, Hans$$b14
000143613 7001_ $$aGoldschmidt, Hartmut$$b15
000143613 773__ $$0PERI:(DE-600)2600560-8$$a10.1038/s41408-019-0206-8$$gVol. 9, no. 4, p. 45$$n4$$p45$$tBlood cancer journal$$v9$$x2044-5385$$y2019
000143613 909CO $$ooai:inrepo02.dkfz.de:143613$$pVDB
000143613 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000143613 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000143613 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143613 9141_ $$y2019
000143613 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD CANCER J : 2017
000143613 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143613 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143613 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143613 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143613 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000143613 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000143613 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000143613 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000143613 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143613 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143613 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143613 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143613 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143613 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBLOOD CANCER J : 2017
000143613 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000143613 980__ $$ajournal
000143613 980__ $$aVDB
000143613 980__ $$aI:(DE-He78)C060-20160331
000143613 980__ $$aUNRESTRICTED